WE CLAIM:

1. A novel anticancer activity exhibiting compound for treating subjects with chronic disorder, comprising of structure in accordance with formula 1



Formula 1

or any derivative thereof, or a stereoisomer or tautomer thereof pharmaceutically acceptable salt thereof, or combination thereof

wherein:

X is H or alkyl group;

Y is carbonyl group bonded to substituted/unsubstituted homo/hetero cyclic ring with atleast one double bond or carboxyl group bonded to alkyl group;

Z is carbonyl/carboxyl group bonded to substituted/unsubstituted homo/hetero cyclic ring with atleast one double bond or alkene or o-alkyl substituted carbamate or carbonyl group bonded to branched alkyl group and

W is H or amide group or carbonyl group bonded to branched alkyl group.

2. The compound as claimed in claim 1 wherein X is selected from a group comprising of

H or C_1-C_5 alkyl group

3. The compound as claimed in claim 1 wherein Y is selected from a group comprising of

   i. Carbonyl group bonded to cyclo pent-3-ene;

   i. Carboxyl group bonded to C_1-C_5 alkyl group;

   ii. Carbonyl group bonded to 5 carbamoyl, 4,5 dihydro 1H pyrrole

iii. Carbonyl group bonded to 4,5 dihydro 1H pyrrole 2 carbamoyl

4. The compound as claimed in claim 1 wherein Z is selected from a group comprising of

   i. o- C_1-C_5 alkyl carbamate;

   i. carbonyl group bonded to 5 carbamoyl, 2,3, dihydro 1H pyrrole;

   ii. carboxyl group bonded to pyridine,

   iii. C_1-C_5 alkene;

   iv. Carbonyl group bonded to C_1-C_6 branched alkyl group;

5. The compound as claimed in claim 1 wherein W is selected from a group comprising of

   Amide group or H or Carbonyl group bonded to C_1-C_5 branched alkyl group.

6. The compound as claimed in claim 1-5 wherein

   X is H

   Y is Carbonyl group bonded to cyclo pent-3-ene

   Z is o-methyl carbamate

   W is amide group

7. The compound as claimed in claim 6 wherein

   X is H

   Y is 

   Z is 

W is 

8. The compound as claimed in claim 1-5 wherein

X is butyl group

Y is Carboxyl group bonded to ethyl group

Z is carbonyl group bonded to 5 carbamoyl, 2,3, dihydro 1H pyrrole

W is H.

9. The compound as claimed in claim 8 wherein

X is 

Y is 

Z is 

W is H

10. The compound as claimed in claim 1-5 wherein

X is H

Y is Carbonyl group bonded to 5 carbamoyl, 4,5 dihydro 1H pyrrole

Z is carboxyl group bonded to pyridine

W is H.

11. The compound as claimed in claim 10 wherein

X is H



Y is



Z is

W is H

12. The compound as claimed in claim 1-5 wherein

X is H

Y is Carbonyl group bonded to 4,5 dihydro 1H pyrrole 2 carbamoyl

Z is ethylene group

W is Carbonyl group bonded to sec propyl group

13. The compound as claimed in claim 12 wherein

X is H



Y is



Z is



W is

14. The compound as claimed in claim 1-5 wherein

X is H

Y is Carbonyl group bonded to 4,5 dihydro 1H pyrrole 2 carbamoyl

Z is Carbonyl group bonded to tertiary butyl group;

W is H.

15. The compound as claimed in claim 14 wherein

X is H

Y is 

Z is 

W is H

16. A pharmaceutical composition, comprising an effective amount of compound of any one of claims 1-15 or a stereoisomer or tautomer thereof and a pharmaceutically acceptable carrier thereof.

17. An article of manufacture, comprising: (i) an effective amount of a compound of any one of claims 1-15 or a stereoisomer or tautomer thereof, or a pharmaceutical composition of claim 16; and (ii) instructions for use in treating a disease, disorder, or condition mediated by KRAS.

18. A kit, comprising: (i) an effective amount of a compound of any one of claims 1-15, or a stereoisomer or tautomer thereof, or a pharmaceutical composition of claim 16; and (ii) instructions for use in treating a disease, disorder, or condition mediated by KRAS.